Tms (4891) · RiskRestated
Long Development Timelines and Uncertainty of Success in New Drug Development
First written in FY2023. 1 of 2 entries say "Restated". Latest entry: FY2025.
2entries
3years
0from disclosures
How it moved
Same theme, other companies
Uncertainty over Prolonged or Discontinued Drug Development Pipelines and CommercializationA theme 69 companies write about · 85 as a headwind · 0 as a tailwind
The whole theme swung hardest in 2022: 20 of 40 companies on the "Worse" side.
28 other companies' latest entry also says "Restated".
Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 69 companies compared. The sentences above are computed from all 69.Full recordFilings, disclosures and news, newest first
- FY2025RestatedAnnual report
「Developing prescription drugs requires substantial R&D investment and considerable time. Success in preclinical or early clinical trials does not necessarily guarantee success in subsequent clinical trials or regulatory approval.」
The Company continues to disclose the risks that development requires substantial investment and time and that trial success and regulatory approval are not guaranteed, including potential delays or discontinuation from regulatory discussions, additional trials or approval conditions. - FY2023First statedAnnual report
「Developing prescription drugs requires substantial R&D investment and considerable time. Success in preclinical or early clinical trials does not necessarily guarantee success in subsequent clinical trials or regulatory approval.」
The Company highlights the risk that substantial investment, lengthy development periods and uncertainty in trial results and approval could lead to delays, discontinuation or abandonment of a launch.